Search All News
Less than two weeks into her retirement, Alfredia learned that she had early stage, HER2-positive breast cancer.
When Lucia discovered she had stage 2 triple-negative breast cancer, she enrolled in the I-SPY2 clinical trail at Columbia.
In an interview with USA Today, Lauren Friedlander, MD, discusses the FDA's new requirements that providers inform patients about their breast density during mammograms.
Source:Mailman School of Public Health
Breast density awareness is linked to heightened uncertainty about cancer risk and screening choices among Spanish-speaking women in Northern Manhattan, according to a study led by Parisa Tehranifar.
- December 16, 2022
A randomized multi-center trial examined the effect of acupuncture on reducing joint pain related to AIs in women with early-stage breast cancer.
- December 9, 2022
A significantly lower proportion of Hispanic and Black women who underwent screening received 3D mammograms, according to a new study presented at the 2022 San Antonio Breast Cancer Symposium.
- October 25, 2022
Melissa Accordino, MD, tackles solutions to long-term side effects, like peripheral neuropathy, that some breast cancer survivors experience after overcoming the disease.
- October 24, 2022
While medical experts agree that women should all get screened, the age at which screening should begin is an area of controversy, leaving patients confused as to what they should do.
- October 5, 2022
Elaine Alden shares her story of overcoming triple-negative breast cancer with the hope of helping and supporting other patients and their families who are affected by cancer.
- July 18, 2022
Under her directorship, Dr. Karen Antman led the expansion of the Cancer Center's clinical arm, infrastructure and multi-disciplinary care.
- December 10, 2021
Researchers from the Herbert Irving Comprehensive Cancer Center presented new research on breast cancer risk prediction at the 2021 San Antonio Breast Cancer Symposium.
- October 29, 2021
Sharon Howell had an encouraging response as a patient in the I-SPY clinical trials, and the outcome could also translate to a lower likelihood of her cancer coming back in the future.
- October 27, 2021
Desiree Walker is dedicated to patient advocacy, driving awareness, community outreach engagement, empowering cancer patients, and linking them to the resources they need during treatment and beyond.